Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=2428
{ "count": 24860, "next": "http://api.gregory-ms.com/articles/?format=api&page=2429", "previous": "http://api.gregory-ms.com/articles/?format=api&page=2427", "results": [ { "article_id": 597, "title": "The IL-27/IL-27R axis is altered in CD4(+) and CD8(+) T lymphocytes from multiple sclerosis patients", "summary": "<div><p>Clin Transl Immunology. 2021 Mar 5;10(3):e1262. doi: 10.1002/cti2.1262. eCollection 2021.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVES: Pro- and anti-inflammatory properties have been attributed to interleukin-27 (IL-27). Nevertheless, the impact of this cytokine on chronic inflammatory diseases such as multiple sclerosis (MS) remains ill-defined. We investigated the biology of IL-27 and its specific receptor IL-27Rα in MS patients.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: Levels of IL-27 and its natural antagonist (IL-27-Rα) were measured by ELISA in biological fluids. CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes were isolated from untreated relapsing-remitting MS patients and healthy donors. Transcriptome-wide analysis compared T-cell subsets stimulated or not with IL-27. Expression of the IL-27Rα, key immune factors, STAT phosphorylation and cytokine production was assessed by flow cytometry.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: We observed elevated levels of IL-27 in the serum and cerebrospinal fluid of MS patients compared with controls. Moreover, we show that specific IL-27-mediated effects on T lymphocytes are reduced in MS patients including the induction of PD-L1. IL-27-triggered STAT3 signalling pathway is enhanced in CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes from MS patients. Elevated IL-27Rα levels in serum from MS patients are sufficient to impair the capacity of IL-27 to act on immune cells. We demonstrate that shedding of IL-27Rα by activated CD4<sup>+</sup> T lymphocytes from MS patients contributes to the increased IL-27Rα peripheral levels and consequently can dampen the IL-27 responsiveness.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: Our work identifies several mechanisms that are altered in the IL-27/IL-27R axis in MS patients, especially in T lymphocytes. Our results underline the importance of characterising the biology of cytokines in human patients prior to design new therapeutics.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33728050/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210317134551&v=2.14.3\">33728050</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7934284/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210317134551&v=2.14.3\">PMC7934284</a> | DOI:<a href=\"https://doi.org/10.1002/cti2.1262\">10.1002/cti2.1262</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33728050/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-03-05T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Wiley", "container_title": "Clinical & Translational Immunology", "authors": [ { "author_id": 244990, "given_name": "Marie‐Laure", "family_name": "Clénet", "ORCID": null, "country": null }, { "author_id": 244992, "given_name": "Cyril", "family_name": "Laurent", "ORCID": null, "country": null }, { "author_id": 244993, "given_name": "Florent", "family_name": "Lemaitre", "ORCID": null, "country": null }, { "author_id": 242796, "given_name": "Negar", "family_name": "Farzam‐kia", "ORCID": null, "country": null }, { "author_id": 163280, "given_name": "Olivier", "family_name": "Tastet", "ORCID": "http://orcid.org/0000-0001-5694-6266", "country": null }, { "author_id": 244994, "given_name": "Odile", "family_name": "Devergne", "ORCID": null, "country": null }, { "author_id": 163289, "given_name": "Boaz", "family_name": "Lahav", "ORCID": "http://orcid.org/0000-0002-0195-3327", "country": null }, { "author_id": 182584, "given_name": "Marc", "family_name": "Girard", "ORCID": "http://orcid.org/0000-0001-8207-8896", "country": null }, { "author_id": 183403, "given_name": "Pierre", "family_name": "Duquette", "ORCID": "http://orcid.org/0000-0001-7231-1754", "country": null }, { "author_id": 156897, "given_name": "Alexandre", "family_name": "Prat", "ORCID": "http://orcid.org/0000-0001-6188-0580", "country": "CA" }, { "author_id": 163294, "given_name": "Catherine", "family_name": "Larochelle", "ORCID": "http://orcid.org/0000-0002-8724-4782", "country": null }, { "author_id": 163295, "given_name": "Nathalie", "family_name": "Arbour", "ORCID": "http://orcid.org/0000-0002-3718-1584", "country": "CA" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-17T17:45:54Z", "noun_phrases": [ "The IL-27/IL-27R axis", "CD4(+", "CD8(+) T", "multiple sclerosis patients" ], "doi": "10.1002/cti2.1262", "access": "open", "takeaways": " Pro- and anti-inflammatory properties have been attributed to interleukin-27 (IL-27) The impact of this cytokine on chronic inflammatory diseases such as multiple sclerosis remains ill-defined .", "categories": [] }, { "article_id": 594, "title": "The prospect of dopaminergic therapy in multiple sclerosis", "summary": "<div><p>Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(2):67-70. doi: 10.17116/jnevro202112102167.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Dopamine is a direct mediator of neuroimmune interactions. Recent studies show that by acting on the dopaminergic receptors, it is possible to modulate Th17-immune response, which play a crucial role in the pathogenesis of multiple sclerosis. Dopamine can modulate Th17 cells function as well as dendritic cell-mediated Th17-immune response that allows considering dopaminergic receptors as a new therapeutic target in multiple sclerosis. In this short communication, the prospects of using dopaminergic therapy as a pathogenetic treatment for multiple sclerosis are discussed.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33728853/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210317134551&v=2.14.3\">33728853</a> | DOI:<a href=\"https://doi.org/10.17116/jnevro202112102167\">10.17116/jnevro202112102167</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33728853/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-01T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Media Sphere Publishing Group", "container_title": "Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova", "authors": [ { "author_id": 165467, "given_name": "M.V.", "family_name": "Melnikov", "ORCID": "http://orcid.org/0000-0001-6880-3668", "country": "RU" }, { "author_id": 202476, "given_name": "M.V.", "family_name": "Pashenkov", "ORCID": "http://orcid.org/0000-0002-6995-1790", "country": null }, { "author_id": 147982, "given_name": "A.N.", "family_name": "Boyko", "ORCID": "http://orcid.org/0000-0002-2975-4151", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-17T17:45:54Z", "noun_phrases": [ "The prospect", "dopaminergic therapy", "multiple sclerosis" ], "doi": "10.17116/jnevro202112102167", "access": "restricted", "takeaways": " Recent studies show that by acting on the dopaminergic receptors, it is possible to modulate Th17-immune response, which play a crucial role in the pathogenesis of multiple sclerosis . Dopamine can mod", "categories": [] }, { "article_id": 596, "title": "Perceived social support, mental health, and marital satisfaction in multiple sclerosis patients", "summary": "<div><p>Perspect Psychiatr Care. 2021 Mar 17. doi: 10.1111/ppc.12760. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">PURPOSE: This study aimed to examine the patients' perceived social support, mental health, and marital satisfaction.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">DESIGN AND METHODS: Data were collected via Patient Information Form, Barthel Index of Activities of Daily Living, Marital Life Scale, Multidimensional Scale of Perceived Social Support, and General Health Questionnaire for 72 patients.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">FINDINGS: Multiple sclerosis (MS) patients had a moderate level of marital satisfaction. The perceived social support showed positive correlation with marital satisfaction and negative correlation with mental health disorders in MS.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">PRACTICE IMPLICATIONS: These results will facilitate the perception of mental problems, marital satisfaction, and social support in MS patients by the nurses.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33728706/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210317134551&v=2.14.3\">33728706</a> | DOI:<a href=\"https://doi.org/10.1111/ppc.12760\">10.1111/ppc.12760</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33728706/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-10T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Wiley", "container_title": "Perspectives in Psychiatric Care", "authors": [ { "author_id": 179667, "given_name": "Şükrü", "family_name": "Özen", "ORCID": "http://orcid.org/0000-0001-7280-9093", "country": null }, { "author_id": 179668, "given_name": "Tuğba", "family_name": "Karataş", "ORCID": "http://orcid.org/0000-0001-8356-6234", "country": null }, { "author_id": 179669, "given_name": "Ülkü", "family_name": "Polat", "ORCID": "http://orcid.org/0000-0002-4293-1394", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-17T17:45:54Z", "noun_phrases": [ "Perceived social support", "mental health", "marital satisfaction", "multiple sclerosis patients" ], "doi": "10.1111/ppc.12760", "access": "restricted", "takeaways": " Multiple sclerosis patients had a moderate level of marital satisfaction . The perceived social support showed positive correlation with marital satisfaction and negative correlation with mental health disorders in MS patients .", "categories": [] }, { "article_id": 593, "title": "Comparing the diagnostic value of Echocardiography In Stroke (CEIS) – results of a prospective observatory cohort study", "summary": "Background: Echocardiography is one of the main diagnostic tools for the diagnostic workup of stroke and is already well integrated into the clinical workup. However, the value of transthoracic vs. transesophageal echocardiography (TTE/TEE) in stroke patients is still a matter of debate. Aim of this study was to characterize relevant findings of TTE and TEE in the management of stroke patients and to correlate them with subsequent clinical decisions and therapies.MethodsWe evaluated n = 107 patients admitted with an ischemic stroke or transient ischemic attack to our stroke unit of our university medical center. They underwent TTE and TEE examination by different blinded investigators.ResultsMajor cardiac risk factors were found in 8 of 98 (8.2%) patients and minor cardiac risk factors for stroke were found in 108 cases. We found a change in therapeutic regime after TTE or TEE in 22 (22.5%) cases, in 5 (5%) cases TEE leads to the change of therapeutic regime, in 4 (4%) TTE and in 13 cases (13.3%) TTE and TEE lead to the same change in therapeutic regime. The major therapy change was the indication to close a patent foramen ovale (PFO) in 9 (9.2%) patients with TTE and in 10 (10.2%) patients with TEE (p = 1.000).ConclusionMajor finding with clinical impact on therapy change is the detection of PFO. But for the detection of PFO, TTE is non inferior to TEE, implicating that TTE serves as a good screening tool for detection of PFO, especially in young age patients.Trial registrationThe trial was registered and approved prior to inclusion by our local ethics committee (1/3/17).", "link": "https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-021-02136-5", "published_date": "2021-03-17T00:00:00Z", "sources": [ "BioMedCentral" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "BMC Neurology", "authors": [ { "author_id": 242109, "given_name": "Marlena", "family_name": "Schnieder", "ORCID": null, "country": null }, { "author_id": 242110, "given_name": "Mohammed", "family_name": "Chebbok", "ORCID": null, "country": null }, { "author_id": 242111, "given_name": "Michael", "family_name": "Didié", "ORCID": null, "country": null }, { "author_id": 242112, "given_name": "Frieder", "family_name": "Wolf", "ORCID": null, "country": null }, { "author_id": 242113, "given_name": "Mostafa", "family_name": "Badr", "ORCID": null, "country": null }, { "author_id": 242114, "given_name": "Ibrahim", "family_name": "Allam", "ORCID": null, "country": null }, { "author_id": 242115, "given_name": "Mathias", "family_name": "Bähr", "ORCID": null, "country": null }, { "author_id": 242116, "given_name": "Gerd", "family_name": "Hasenfuß", "ORCID": null, "country": null }, { "author_id": 242117, "given_name": "Jan", "family_name": "Liman", "ORCID": null, "country": null }, { "author_id": 242118, "given_name": "Marco Robin", "family_name": "Schroeter", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-17T15:06:22Z", "noun_phrases": [ "the diagnostic value", "Echocardiography", "Stroke", "CEIS", "a prospective observatory cohort study" ], "doi": "10.1186/s12883-021-02136-5", "access": "open", "takeaways": " The value of transthoracic vs. transesophageal echocardiography (TTE/TEE) in stroke patients is still a matter of debate . Aim of study was to characterize relevant findings of TTE and TEE in the management of stroke patients .", "categories": [] }, { "article_id": 592, "title": "Immune-related genes of the larval Holotrichia parallela in response to entomopathogenic nematodes Heterorhabditis beicherriana LF", "summary": "Background: Entomopathogenic nematodes (EPNs) emerge as compatible alternatives to conventional insecticides in controlling Holotrichia parallela larvae (Coleoptera: Scarabaeidae). However, the immune responses of H. parallela against EPNs infection remain unclear.ResultsIn present research, RNA-Seq was firstly performed. A total of 89,427 and 85,741 unigenes were achieved from the midgut of H. parallela larvae treated with Heterorhabditis beicherriana LF for 24 and 72 h, respectively; 2545 and 3156 unigenes were differentially regulated, respectively. Among those differentially expressed genes (DEGs), 74 were identified potentially related to the immune response. Notably, some immune-related genes, such as peptidoglycan recognition protein SC1 (PGRP-SC1), pro-phenoloxidase activating enzyme-I (PPAE-I) and glutathione s-transferase (GST), were induced at both treatment points. Bioinformatics analysis showed that PGRP-SC1, PPAE-I and GST were all involved in anti-parasitic immune process. Quantitative real-time PCR (qRT-PCR) results showed that the three immune-related genes were expressed in all developmental stages; PGRP-SC1 and PPAE-I had higher expressions in midgut and fat body, respectively, while GST exhibited high expression in both of them. Moreover, in vivo silencing of them resulted in increased susceptibility of H. parallela larvae to H. beicherriana LF.ConclusionThese results suggest that H. parallela PGRP-SC1, PPAE-I and GST are involved in the immune responses to resist H. beicherriana LF infection. This study provides the first comprehensive transcriptome resource of H. parallela exposure to nematode challenge that will help to support further comparative studies on host-EPN interactions.", "link": "https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-021-07506-4", "published_date": "2021-03-17T00:00:00Z", "sources": [ "BioMedCentral" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "BMC Genomics", "authors": [ { "author_id": 245932, "given_name": "Ertao", "family_name": "Li", "ORCID": null, "country": null }, { "author_id": 245933, "given_name": "Jianhui", "family_name": "Qin", "ORCID": null, "country": null }, { "author_id": 245934, "given_name": "Honglin", "family_name": "Feng", "ORCID": null, "country": null }, { "author_id": 245935, "given_name": "Jinqiao", "family_name": "Li", "ORCID": null, "country": null }, { "author_id": 245936, "given_name": "Xiaofeng", "family_name": "Li", "ORCID": null, "country": null }, { "author_id": 245937, "given_name": "Innocent", "family_name": "Nyamwasa", "ORCID": null, "country": null }, { "author_id": 245938, "given_name": "Yazhong", "family_name": "Cao", "ORCID": null, "country": null }, { "author_id": 245939, "given_name": "Weibin", "family_name": "Ruan", "ORCID": null, "country": null }, { "author_id": 245940, "given_name": "Kebin", "family_name": "Li", "ORCID": null, "country": null }, { "author_id": 150529, "given_name": "Jiao", "family_name": "Yin", "ORCID": "http://orcid.org/0000-0003-0705-6085", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-17T15:06:22Z", "noun_phrases": [ "Immune-related genes", "the larval", "response", "entomopathogenic nematodes", "Heterorhabditis beicherriana LF" ], "doi": "10.1186/s12864-021-07506-4", "access": "open", "takeaways": " Entomopathogenic nematodes (EPNs) emerge as compatible alternatives to conventional insecticides in controlling Holotrichia parallela larvae . The immune responses of H. parallela against EPNs infection remain unclear .", "categories": [] }, { "article_id": 591, "title": "Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis", "summary": "<div><p>Neurol Neuroimmunol Neuroinflamm. 2021 Mar 16;8(3):e979. doi: 10.1212/NXI.0000000000000979. Print 2021 May.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: To describe the dynamics of brain volume loss (BVL) at different stages of relapsing-remitting multiple sclerosis (RRMS), to describe the association between BVL and clinical measures, and to investigate an effect of treatment escalation on the rate of BVL.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: Together, 1903 patients predominantly with RRMS from the Avonex-Steroids-Azathioprine cohort (N = 166), the study of early IFN-β1a treatment cohort (N = 180), and the quantitative MRI cohort (N = 1,557) with ≥2 MRI scans and ≥1-year of follow-up were included. Brain MRI scans (N = 7,203) were performed using a single 1.5-T machine. Relationships between age or disease duration and global and tissue-specific BVL rates were analyzed using mixed models.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: Age was not associated with the rate of BVL (β = -0.003; Cohen f2 = 0.0005; adjusted <i>p</i> = 0.39). Although disease duration was associated with the rate of BVL, its effect on the BVL rate was minimal (β = -0.012; Cohen f2 = 0.004; adjusted <i>p</i> = 4 × 10<sup>-5</sup>). Analysis of association between tissue-specific brain volume changes and age (β = -0.019 to -0.011; adjusted <i>p</i> = 0.028-1.00) or disease duration (β = -0.028 to -0.008; adjusted <i>p</i> = 0.16-0.96) confirmed these results. Although increase in the relapse rate (β = 0.10; adjusted <i>p</i> = 9 × 10<sup>-9</sup>), Expanded Disability Status Scale (EDSS; β = 0.17; adjusted <i>p</i> = 8 × 10<sup>-5</sup>), and EDSS change (β = 0.15; adjusted <i>p</i> = 2 × 10<sup>-5</sup>) were associated with accelerated rate of BVL, their effect on the rate of BVL was minimal (all Cohen f2 ≤ 0.007). In 94 patients who escalated therapy, the rate of BVL decreased following treatment escalation by 0.29% (β = -0.29; Cohen f2 = 0.133; <i>p</i> = 5.5 × 10<sup>-8</sup>).</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSIONS: The rate of BVL is relatively stable throughout the course of RRMS. The accelerated BVL is weakly associated with concurrent higher disease activity, and timely escalation to high-efficacy immunotherapy helps decrease the rate of BVL.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33727311/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210317072551&v=2.14.3\">33727311</a> | DOI:<a href=\"https://doi.org/10.1212/NXI.0000000000000979\">10.1212/NXI.0000000000000979</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33727311/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-03-16T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Ovid Technologies (Wolters Kluwer Health)", "container_title": "Neurology - Neuroimmunology Neuroinflammation", "authors": [ { "author_id": 220348, "given_name": "Tomas", "family_name": "Uher", "ORCID": "http://orcid.org/0000-0002-3241-4713", "country": null }, { "author_id": 322817, "given_name": "Jan", "family_name": "Krasensky", "ORCID": "http://orcid.org/0000-0002-5605-8821", "country": null }, { "author_id": 260602, "given_name": "Charles", "family_name": "Malpas", "ORCID": null, "country": null }, { "author_id": 143256, "given_name": "Niels", "family_name": "Bergsland", "ORCID": "http://orcid.org/0000-0002-7792-0433", "country": null }, { "author_id": 242244, "given_name": "Michael G.", "family_name": "Dwyer", "ORCID": null, "country": null }, { "author_id": 258349, "given_name": "Eva", "family_name": "Kubala Havrdova", "ORCID": null, "country": null }, { "author_id": 317884, "given_name": "Manuela", "family_name": "Vaneckova", "ORCID": "http://orcid.org/0000-0002-8784-7997", "country": null }, { "author_id": 241018, "given_name": "Dana", "family_name": "Horakova", "ORCID": null, "country": null }, { "author_id": 143251, "given_name": "Robert", "family_name": "Zivadinov", "ORCID": "http://orcid.org/0000-0002-7799-1485", "country": null }, { "author_id": 160181, "given_name": "Tomas", "family_name": "Kalincik", "ORCID": "http://orcid.org/0000-0003-3778-1376", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-17T11:25:53Z", "noun_phrases": [ "Evolution", "Brain Volume Loss Rates", "Early Stages", "Multiple Sclerosis" ], "doi": "10.1212/NXI.0000000000000979", "access": "open", "takeaways": " Brain volume loss (BVL) at different stages of relapsing-remitting multiple sclerosis (RRMS) is stable throughout the course of RRMS . In 94 patients who escalated therapy, the rate of BVL decreased following treatment escalation by 0.29% (β = -0.29)", "categories": [] }, { "article_id": 589, "title": "ILC in chronic inflammation, cancer and targeting with biologicals", "summary": "<div><p>Mol Aspects Med. 2021 Mar 14:100963. doi: 10.1016/j.mam.2021.100963. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Since their discovery, Innate Lymphoid Cells (ILC) have emerged as important effector cells, serving multiple roles in maintaining tissue homeostasis and responding to tissue insults. As such, dysregulations of their function and distribution have been observed in a variety of immune-mediated diseases, suggesting a specific role for ILC in the pathophysiology of several disorders including chronic inflammation and cancer. Here, we provide an updated view on ILC biology dissecting their pathological or protective contribution in chronic inflammatory diseases such as multiple sclerosis, inflammatory bowel diseases, psoriasis, rheumatoid arthritis, asthma and COPD, atherosclerosis, also exploring ILC role in tumor surveillance and progression. Throughout the review, we will also highlight how the potential dual role of these cells for protective or pathogenic immunity in many inflammatory diseases makes them interesting targets for the development of novel therapeutic strategies, particularly promising.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33726947/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210317072551&v=2.14.3\">33726947</a> | DOI:<a href=\"https://doi.org/10.1016/j.mam.2021.100963\">10.1016/j.mam.2021.100963</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33726947/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-08T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Elsevier BV", "container_title": "Molecular Aspects of Medicine", "authors": [ { "author_id": 244844, "given_name": "Claudia", "family_name": "De Pasquale", "ORCID": null, "country": null }, { "author_id": 244846, "given_name": "Stefania", "family_name": "Campana", "ORCID": null, "country": null }, { "author_id": 244848, "given_name": "Irene", "family_name": "Bonaccorsi", "ORCID": null, "country": null }, { "author_id": 244849, "given_name": "Paolo", "family_name": "Carrega", "ORCID": null, "country": null }, { "author_id": 244851, "given_name": "Guido", "family_name": "Ferlazzo", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-17T11:25:53Z", "noun_phrases": [ "ILC", "chronic inflammation", "cancer", "biologicals" ], "doi": "10.1016/j.mam.2021.100963", "access": "restricted", "takeaways": " Innate Lymphoid Cells have emerged as important effector cells, serving multiple roles in maintaining tissue homeostasis and responding to tissue insults . Dysregulations of their function and distribution have been observed in a variety of immune-mediated diseases .", "categories": [] }, { "article_id": 590, "title": "Web-based physical activity intervention for people with progressive multiple sclerosis: application of consensus-based intervention development guidance", "summary": "<div><p>BMJ Open. 2021 Mar 16;11(3):e045378. doi: 10.1136/bmjopen-2020-045378.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVES: People with progressive multiple sclerosis (PwPMS) report that they recognise the benefits of activity on their physical and psychological health but need support to achieve their physical activity goals. We aimed to systematically develop a theoretically informed intervention that would enable PwPMS to more readily engage in regular physical activity.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">DESIGN: We used an intervention mapping approach to inform intervention development.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">SETTING: We conducted semistructured interviews with PwPMS and their families/carers and physiotherapists recruited from secondary care settings.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">PARTICIPANTS: Fourteen PwPMS with an Expanded Disability Status Scale score of between 6 and 8 and 7 of their families/carers and 13 physiotherapists and 1 physiotherapy technician participated.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: Interview data suggested that the development of supportive coaching relationships with physiotherapists could promote the ability of PwPMS to achieve a desirable and achievable physical activity plan. These interview data informed the prototype 'Lifestyle Exercise and Activity Package for Multiple Sclerosis' (LEAP-MS) consisting of a secure multiuser web-based platform (with an education and activity suite, interactive components enabling selection of exercises, goal setting and activity logging), up to six flexible face-to-face or web-based physiotherapy coaching sessions and remote support via an embedded web-based messaging function that all together draw on specific theory-based methods to achieve physical activity behaviour change, namely active learning, reinforcement, modelling, feedback, facilitation, goal setting and guided practice. Implementation is within a multiuser platform accessible to participants, trained physiotherapists and researchers.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSIONS: We have followed an inclusive, systematic and transparent process to develop the LEAP-MS intervention that enables detailed description of components, context and guiding principles to inform ongoing evaluation. Importantly, PwPMS expressed the need for autonomy in developing physical activity plans. This has been achieved through the embedding of self-management principles in the design and delivery of the LEAP-MS intervention.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33727274/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210317072551&v=2.14.3\">33727274</a> | DOI:<a href=\"https://doi.org/10.1136/bmjopen-2020-045378\">10.1136/bmjopen-2020-045378</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33727274/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-03-16T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "BMJ", "container_title": "BMJ Open", "authors": [ { "author_id": 152548, "given_name": "Monica", "family_name": "Busse", "ORCID": "http://orcid.org/0000-0002-5331-5909", "country": null }, { "author_id": 192073, "given_name": "Julie", "family_name": "Latchem-Hastings", "ORCID": "http://orcid.org/0000-0001-6738-916X", "country": null }, { "author_id": 244856, "given_name": "Kate", "family_name": "Button", "ORCID": null, "country": null }, { "author_id": 224240, "given_name": "Vince", "family_name": "Poile", "ORCID": "http://orcid.org/0000-0002-5770-5584", "country": "GB" }, { "author_id": 224241, "given_name": "Freya", "family_name": "Davies", "ORCID": "http://orcid.org/0000-0002-6956-1100", "country": null }, { "author_id": 244858, "given_name": "Rhian", "family_name": "O' Halloran", "ORCID": null, "country": null }, { "author_id": 244859, "given_name": "Barbara", "family_name": "Stensland", "ORCID": null, "country": null }, { "author_id": 244860, "given_name": "Emma", "family_name": "Tallantyre", "ORCID": null, "country": null }, { "author_id": 244861, "given_name": "Rachel", "family_name": "Lowe", "ORCID": null, "country": null }, { "author_id": 224243, "given_name": "Fiona", "family_name": "Wood", "ORCID": "http://orcid.org/0000-0001-7397-4074", "country": null }, { "author_id": 244862, "given_name": "Helen", "family_name": "Dawes", "ORCID": null, "country": null }, { "author_id": 244863, "given_name": "Adrian", "family_name": "Edwards", "ORCID": null, "country": null }, { "author_id": 244864, "given_name": "Fiona", "family_name": "Jones", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-17T11:25:53Z", "noun_phrases": [ "Web-based physical activity intervention", "people", "progressive multiple sclerosis", "application", "consensus-based intervention development guidance" ], "doi": "10.1136/bmjopen-2020-045378", "access": "open", "takeaways": " People with progressive multiple sclerosis (PwPMS) report that they recognise the benefits of activity on their physical and psychological health but need support to achieve their physical activity goals .", "categories": [] }, { "article_id": 587, "title": "Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab", "summary": "<div><p>Neurologia. 2021 Mar 13:S0213-4853(21)00026-8. doi: 10.1016/j.nrl.2021.01.010. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Late-onset neutropaenia is defined as an absolute neutrophil count of <1.5×10<sup>3</sup>cells/μL starting>4 weeks after the last dose of rituximab, in the absence of other identifiable causes. Late-onset neutropaenia is a rare adverse reaction to rituximab (observed in approximately 5% of patients). Rheumatic diseases constitute the main indication for rituximab; in these patients, neutropaenia appears after a mean of>28 days. Ocrelizumab is another monoclonal antibody that binds to CD20 (a glycosylated phosphoprotein mainly expressed on the membranes of B-lymphocytes); in January 2018, it was approved for the treatment of relapsing-remitting and primary progressive multiple sclerosis. We present a case of neutropaenia following intravenous infusion of ocrelizumab in a patient with primary progressive multiple sclerosis who presented with neutropaenic fever, herpetic stomatitis, and ecthyma gangrenosum only 20 days after infusion.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33726971/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210317072551&v=2.14.3\">33726971</a> | DOI:<a href=\"https://doi.org/10.1016/j.nrl.2021.01.010\">10.1016/j.nrl.2021.01.010</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33726971/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-12-19T00:31:08.719000Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Elsevier BV", "container_title": "Neurología", "authors": [ { "author_id": 244823, "given_name": "E.M.", "family_name": "Alba Suárez", "ORCID": null, "country": null }, { "author_id": 244824, "given_name": "A.", "family_name": "Tallón Barranco", "ORCID": null, "country": null }, { "author_id": 244825, "given_name": "I.", "family_name": "Puertas Muñoz", "ORCID": null, "country": null }, { "author_id": 244826, "given_name": "B.", "family_name": "Chamorro Hernández", "ORCID": null, "country": null }, { "author_id": 244827, "given_name": "Á.", "family_name": "Robles Marhuenda", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-17T11:25:53Z", "noun_phrases": [ "Non-late-onset neutropaenia following treatment", "multiple sclerosis", "ocrelizumab" ], "doi": "10.1016/j.nrl.2021.01.010", "access": "open", "takeaways": " Late-onset neutropaenia is a rare adverse reaction to rituximab (observed in approximately 5% of patients) Rheumatic diseases constitute the main indication for ritukimab . In January 2018, it was approved for the treatment of relapsing-remitting and primary progressive multiple", "categories": [ { "category_id": 8, "category_description": "", "category_name": "Ocrelizumab", "category_slug": "ocrelizumab", "category_terms": [ "ocrelizumab", "ocrevus" ], "article_count": 234 } ] }, { "article_id": 588, "title": "The relationship between BAFF serum levels, anti-NMDAR autoantibodies and fatigue in patients with systemic lupus erythematosus and multiple sclerosis", "summary": "<div><p>Autoimmun Rev. 2021 Mar 13:102802. doi: 10.1016/j.autrev.2021.102802. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33727153/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210317072551&v=2.14.3\">33727153</a> | DOI:<a href=\"https://doi.org/10.1016/j.autrev.2021.102802\">10.1016/j.autrev.2021.102802</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33727153/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-05T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Elsevier BV", "container_title": "Autoimmunity Reviews", "authors": [ { "author_id": 300155, "given_name": "Fabio", "family_name": "Basta", "ORCID": null, "country": null }, { "author_id": 300156, "given_name": "Tamara", "family_name": "Möckel", "ORCID": null, "country": null }, { "author_id": 300157, "given_name": "Jan", "family_name": "Petersohn", "ORCID": null, "country": null }, { "author_id": 300158, "given_name": "Myriam", "family_name": "Meineck", "ORCID": null, "country": null }, { "author_id": 300159, "given_name": "Konstantinos", "family_name": "Triantafyllias", "ORCID": null, "country": null }, { "author_id": 154539, "given_name": "Sinah", "family_name": "Engel", "ORCID": "http://orcid.org/0000-0002-9051-9062", "country": null }, { "author_id": 282273, "given_name": "Arndt", "family_name": "Weinmann", "ORCID": null, "country": null }, { "author_id": 154547, "given_name": "Felix", "family_name": "Luessi", "ORCID": "http://orcid.org/0000-0003-4334-4199", "country": null }, { "author_id": 300160, "given_name": "Julia", "family_name": "Weinmann-Menke", "ORCID": null, "country": null }, { "author_id": 300161, "given_name": "Andreas", "family_name": "Schwarting", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-17T11:25:53Z", "noun_phrases": [ "The relationship", "BAFF serum levels", "anti-NMDAR autoantibodies", "fatigue", "patients", "systemic lupus erythematosus", "multiple sclerosis" ], "doi": "10.1016/j.autrev.2021.102802", "access": "restricted", "takeaways": "", "categories": [] } ] }